New translational research platform launched to study rare cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community. The joint initiative will create a catalog of rare cancer models and provide a data resource to accelerate the identification of therapeutics to treat patients diagnosed with rare tumor types.
The National Cancer Institute defines a rare cancer as one with fewer than 40,000 new cases per year. Cumulatively, rare cancers account for roughly one-quarter of all cancer cases and cancer deaths, but the low incidence of each different type of rare tumor presents a significant challenge to efforts to identify effective therapeutic approaches.
Date Time
New Technique Predicts Response of Brain Tumors to Chemoradiation
AUSTIN, Texas – A team studying malignant brain tumors has developed a new technique for predicting how individual patients will respond to chemoradiation, a major step forward in efforts to personalize cancer treatment.
Researchers at The University of Texas at Austin’s Oden Institute for Computational Engineering and Sciences, Texas Advanced Computing Center (TACC) and The University of Texas MD Anderson Cancer Center have merged various quantitative imaging measurements with computational simulations to create an accurate model for calculating the progression of high-grade glioma.
High-grade gliomas are the most common cancerous primary brain tumors found in adults. Current treatments involve surgical resection of the tumor followed by radiation therapy and chemotherapy. Despite this aggressive treatment, prognosis for patients who undergo this approach is generally poor. The growth and behavior of
Date Time
Share
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer and surrounding normal lung tissue at single-cell resolution, providing a valuable resource for studying tumor development and identifying new therapeutic targets. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.
The findings reveal a heterogeneous lung cancer ecosystem, with extensive interactions between cancer cells and the surrounding microenvironment that regulate early cancer development. By studying the crosstalk between the tumor and surrounding immune cells, researchers identified and validated CD24, an immune checkpoint protein, as a new immunotherapy target for lung cancer treatment.
Rising Incidence and Mortality for Essential Thrombocythaemia medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Note From the Editors
The pace of impact through digital health in 2021 is off to a rapid start be it the number of transactions, the numerous legislative proposals and actions, or the focused attention of enforcement bodies. Given the accelerated pace of tech-enabled methods, such as telehealth or product development through streamlined digital tools and decentralized clinical trials, not to mention AI and big data s impact on diagnostic and research capacity, the policy and regulatory spotlight on digital health will no doubt be bright throughout this year. In the Industry Insights contribution for this issue, several of our digital health experts briefly summarize the focused attention of U.S. enforcement agencies on telehealth given significantly increased reimbursement trends in the area.